MetAP2 as a Target for Obesity and Type 2 Diabetes
Author Information
Author(s): Moon Dong Oh
Primary Institution: Department of Biology Education, Daegu University
Hypothesis
MetAP2 is a promising therapeutic target for obesity and type 2 diabetes due to its role in regulating lipid metabolism and energy balance.
Conclusion
MetAP2 inhibitors show potential in reducing body weight and improving metabolic parameters in obesity and type 2 diabetes.
Supporting Evidence
- MetAP2 plays a critical role in lipid metabolism and energy balance.
- Pharmacological inhibition of MetAP2 has shown promise in reducing body weight and improving glucose tolerance.
- Several MetAP2 inhibitors have demonstrated potential in preclinical and early clinical trials.
Takeaway
MetAP2 is like a helper in our body that can be targeted to help people lose weight and manage diabetes better.
Methodology
This review analyzes the structural characteristics, catalytic mechanisms, and therapeutic potential of MetAP2 inhibitors.
Potential Biases
Potential bias in the selection of studies reviewed.
Limitations
The review does not provide new experimental data and relies on existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website